

# **Antitargets**

Prediction and Prevention of Drug Side Effects

*Edited by*

*Roy J. Vaz and Thomas Klabunde*



**WILEY-  
VCH**

WILEY-VCH Verlag GmbH & Co. KGaA



## **Antitargets**

*Edited by*

*Roy J. Vaz and Thomas Klabunde*

## ***Methods and Principles in Medicinal Chemistry***

Edited by R. Mannhold, H. Kubinyi, G. Folkers

Editorial Board

H. Timmerman, J. Vacca, H. van de Waterbeemd, T. Wieland

### ***Previous Volumes of this Series:***

M. Hamacher, K. Marcus, K. Stühler,  
A. van Hall, B. Warscheid,  
H. E. Meyer (eds.)

#### **Proteomics in Drug Research**

**Vol. 28**

2006, ISBN: 978-3-527-31226-9

D. J. Triggle, M. Gopalakrishnan,  
D. Rampe, W. Zheng (eds.)

#### **Voltage-Gated Ion Channels as Drug Targets**

**Vol. 29**

2006, ISBN: 978-3-527-31258-0

D. Rognan (ed.)

#### **Ligand Design for G Protein-coupled Receptors**

**Vol. 30**

2006, ISBN: 978-3-527-31284-9

D. A. Smith, H. van de Waterbeemd,  
D. K. Walker

#### **Pharmacokinetics and Metabolism in Drug Design, 2nd Ed.**

**Vol. 31**

2006, ISBN: 978-3-527-31368-6

T. Langer, R. D. Hofmann (eds.)

#### **Pharmacophores and Pharmacophore Searches**

**Vol. 32**

2006, ISBN: 978-3-527-31250-4

E. Francotte, W. Lindner (eds.)

#### **Chirality in Drug Research**

**Vol. 33**

2006, ISBN: 978-3-527-31076-0

W. Jahnke, D. A. Erlanson (eds.)

#### **Fragment-based Approaches in Drug Discovery**

**Vol. 34**

2006, ISBN: 978-3-527-31291-7

J. Hüser (ed.)

#### **High-Throughput Screening in Drug Discovery**

**Vol. 35**

2006, ISBN: 978-3-527-31283-2

K. Wanner, G. Höfner (eds.)

#### **Mass Spectrometry in Medicinal Chemistry**

**Vol. 36**

2007, ISBN: 978-3-527-31456-0

R. Mannhold (ed.)

#### **Molecular Drug Properties**

**Vol. 37**

2008, ISBN: 978-3-527-31755-4

# **Antitargets**

Prediction and Prevention of Drug Side Effects

*Edited by*

*Roy J. Vaz and Thomas Klabunde*



**WILEY-  
VCH**

WILEY-VCH Verlag GmbH & Co. KGaA

#### Series Editors

**Prof. Dr. Raimund Mannhold**

Molecular Drug Research Group  
Heinrich-Heine-Universität  
Universitätsstrasse 1  
40225 Düsseldorf  
Germany  
mannhold@uni-duesseldorf.de

**Prof. Dr. Hugo Kubinyi**

Donnersbergerstrasse 9  
67256 Weisenheim am Sand  
Germany  
kubinyi@t-online.de

**Prof. Dr. Gerd Folkers**

Collegium Helveticum  
STW/ETH Zurich  
8092 Zurich  
Switzerland  
folkers@collegium.ethz.ch

#### Volume Editors

**Dr. Roy J. Vaz**

Sanofi-Aventis  
Route 202-206  
Bridgewater, NJ 08807  
USA  
Roy.Vaz@sanofi-aventis.com

**Dr. Thomas Klabunde**

Sanofi-Aventis Deutschland  
Industriepark Höchst G878  
65926 Frankfurt  
Germany  
Thomas.Klabunde@sanofi-aventis.com

#### Cover Illustration

The cover shows a model of the hERG ion channel in the lower left (chapter 4), a CYP structure, lower right (chapter 10), a pharmacophore model for the  $\alpha_1$  adrenergic receptor, upper right (chapter 6) and a schematic of the intestinal epithelium with some transporters, upper left (chapter 15).

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:** applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Bibliographic information published by the Deutsche Nationalbibliothek**

Die Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <<http://dnb.d-nb.de>>.

© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

**Typesetting** Thomson Digital, Noida, India

**Printing** betz-druck GmbH, Darmstadt

**Binding** Litges & Dopf GmbH, Heppenheim

**Cover Design** Grafik-Design Schulz, Fußgönheim

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**ISBN:** 978-3-527-31821-6

## Contents

<b>List of Contributors</b>	<b>XV</b>
<b>Preface</b>	<b>XIX</b>
<b>A Personal Foreword</b>	<b>XXI</b>

<b>I</b>	<b>General Aspects</b>	<b>1</b>
<b>1</b>	<b>Why Drugs Fail – A Study on Side Effects in New Chemical Entities</b>	<b>3</b>
	<i>Daniela Schuster, Christian Laggner, Thierry Langer</i>	
1.1	Introduction	3
1.2	Drugs Withdrawn from the Market between 1992 and 2006	
	Listed Alphabetically	4
1.2.1	Amineptine	4
1.2.2	Aminophenazone (Aminopyrine)	5
1.2.3	Astemizole	5
1.2.4	Bromfenac Sodium	6
1.2.5	Cerivastatin	6
1.2.6	Chlormezanone	6
1.2.7	Fenfluramine and Dexfenfluramine	7
1.2.8	Flosequinan	7
1.2.9	Glafenine	7
1.2.10	Grepafloxacin	8
1.2.11	Levacetylmethadol	8
1.2.12	Mibefradil	9
1.2.13	Rapacuronium Bromide	9
1.2.14	Rofecoxib	10
1.2.15	Temafloxacin	10
1.2.16	Troglitazone	10
1.2.17	Ximelagatran	11
1.3	Borderline Cases	12
1.4	Investigational Drugs That Failed in Clinical Phases from 1992 to 2002	12

1.4.1	A Case Study: Fialuridine	12
1.4.2	A Recent Case Study: Torcetrapib	14
1.4.3	General Reasons for Project Failing in Clinical Phases I–III	15
1.5	Strategies for Avoiding Failure	16
1.6	An Unusual Case: The Revival of Thalidomide	17
	References	18
<b>2</b>	<b>Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure–<i>In Vitro</i> (Pharmacology–ADME)–<i>In Vivo</i> (Safety) Relationships</b>	<b>23</b>
	<i>Jonathan S. Mason, Jacques Migeon, Philippe Dupuis, Annie Otto-Bruc</i>	
2.1	Introduction	23
2.1.1	Biological Profiling/Fingerprints and Drug Discovery Applications	23
2.1.2	Polypharmacology of Drugs	26
2.2	The BioPrint® Approach	28
2.2.1	BioPrint® – General	28
2.2.2	BioPrint® Assay Selection and Profile Description	28
2.2.3	Compounds in BioPrint®	30
2.2.4	BioPrint® <i>In Vivo</i> Data sets	31
2.2.4.1	Compound Details	31
2.2.4.2	ADR Data	31
2.2.4.3	Pharmacokinetics	31
2.2.4.4	Toxicity Data	32
2.3	Structure– <i>In Vitro</i> Relationships	32
2.3.1	Similarity, Chemotypes – What Is a Biologically Relevant Descriptor?	32
2.3.2	Using Biological Fingerprints as a Meaningful Descriptor for Drug Leads and Candidates	33
2.3.2.1	Differentiation of Leads	33
2.3.2.2	Analysis of Attrited Compounds	36
2.3.3	Structural versus Experimental Differentiation – Dependence on Structure-Derived Descriptor Used	37
2.3.4	Predictive Models from Pharmacological Data	40
2.3.5	Predictive Models from ADME Data – BioPrint® Learnings	41
2.4	Chemogenomic Analysis – Target–Target Relationships	41
2.5	<i>In Vitro</i> – <i>In Vivo</i> Relationships – Placing Drug Candidates in the Context of BioPrint®	42
2.5.1	Analyzing Potential ADR Liabilities Based on Individual Hits	43
2.5.2	Analyzing Potential ADR Liabilities Based on Profile Similarity	49
2.6	A Perspective for the Future	50
	References	50



<b>II</b>	<b>Antitargets: Ion Channels and GPCRs</b>	<b>53</b>
<b>3</b>	<b>Pharmacological and Regulatory Aspects of QT Prolongation</b>	<b>55</b>
	<i>Fabrizio De Ponti</i>	
3.1	Introduction	55
3.2	hERG: Target Versus Antitarget	57
3.3	Pharmacology of QT Prolongation	58
3.3.1	Multiple Mechanisms Leading to QT Prolongation	59
3.3.2	hERG as the Key Mechanism for the Drug-Induced Long QT Syndrome	59
3.3.3	Pharmacogenetic Aspects	60
3.4	Significance of Drug-Induced QT Prolongation	61
3.4.1	Prolonged QT/QTc and Occurrence of TdP	61
3.4.2	Dose–Response Relationship for QT Prolongation	66
3.5	Regulatory Aspects of QT Prolongation	67
3.5.1	Regulatory Guidance Documents	67
3.5.2	Preclinical <i>In Vitro</i> and <i>In Vivo</i> Studies	68
3.5.3	Clinical Studies	72
3.6	Conclusions	76
	References	77
<b>4</b>	<b>hERG Channel Physiology and Drug-Binding Structure–Activity Relationships</b>	<b>89</b>
	<i>Sarah Dalibalta, John S. Mitcheson</i>	
4.1	Introduction	89
4.2	hERG Channel Structure	90
4.3	hERG Potassium Channels and the Cardiac Action Potential	91
4.4	Mutations in hERG Are Associated with Cardiac Arrhythmias	93
4.5	Acquired Long QT Syndrome	94
4.6	Drug-Binding Site of hERG	95
4.7	Structural Basis for hERG Block	95
4.8	Alternative Mechanisms of Block	97
4.9	Role of Inactivation in hERG Block	98
4.10	Inhibition of hERG Trafficking by Pharmacological Agents	99
4.11	Computational Approaches to Predict hERG K <sup>+</sup> Channel Block	99
4.12	Conclusions	101
	References	102
<b>5</b>	<b>QSAR and Pharmacophores for Drugs Involved in hERG Blockage</b>	<b>109</b>
	<i>Maurizio Recanatini, Andrea Cavalli</i>	
5.1	Introduction	109
5.2	Ligand-Based Models for hERG-Blocking Activity	110
5.2.1	3D QSAR	111
5.2.2	2D QSAR	113

5.2.3	Classification Models	116
5.3	Ligand-Derived Models in the Light of the hERG Channel Structure	119
5.4	Conclusions	121
	References	123
<b>6</b>	<b>GPCR Antitarget Modeling: Pharmacophore Models to Avoid GPCR-Mediated Side Effects</b>	<b>127</b>
	<i>Thomas Klabunde, Andreas Evers</i>	
6.1	Introduction: GPCRs as Antitargets	127
6.2	<i>In Silico</i> Tools for GPCR Antitarget Modeling	129
6.3	GPCR Antitarget Pharmacophore Modeling: The $\alpha_{1a}$ Adrenergic Receptor	130
6.3.1	Generation of Cross-Chemotype Pharmacophore Models	131
6.3.2	Description of Cross-Chemotype Pharmacophore Models	131
6.3.3	Validation of Antitarget Pharmacophore Models	132
6.3.3.1	Virtual Screening: Hit Rates and Yields	132
6.3.3.2	Virtual Screening: Fit Values and Enrichment Factors	134
6.3.4	Mapping of Pharmacophore Models into Receptor Site	135
6.3.5	Guidance of Chemical Optimization to Avoid GPCR-Mediated Side Effects	138
6.4	Summary	139
	References	140
<b>7</b>	<b>The Emergence of Serotonin 5-HT<sub>2B</sub> Receptors as DRUG Antitargets</b>	<b>143</b>
	<i>Vincent Setola, Bryan L. Roth</i>	
7.1	Receptorome Screening to Identify Drug Targets and Antitargets	144
7.2	Post-Receptorome Screening Data Implicate 5-HT <sub>2B</sub> Receptors in Drug-Induced VHD and PH	145
7.3	Drug Structural Classes and VHD/PH	149
7.4	Conclusions	150
	References	151
<b>8</b>	<b>Computational Modeling of Selective Pharmacophores at the <math>\alpha_1</math>-Adrenergic Receptors</b>	<b>155</b>
	<i>Francesca Fanelli, Pier G. De Benedetti</i>	
8.1	Introduction	155
8.2	Ligand-Based and Receptor-Based Pharmacophore Modeling and QSAR Analysis	158
8.3	The General $\alpha_1$ -AR Pharmacophore	161
8.3.1	Ligand-Based Pharmacophore and Virtual Screening	161
8.3.1.1	Prazosin Analogues (2,4-Diamino-6,7-dimethoxyquinazoline Derivatives)	163
8.3.1.2	1,4-Benzodioxan (WB-4101) Related Compounds	166

8.3.1.3	Arylpiperazine Derivatives	167
8.3.1.4	Target and Antitarget Pharmacophore Modeling	168
8.4	Modeling the $\alpha_1$ -AR Subtype Selectivities of Different Classes of Antagonists	170
8.4.1	Supermolecule-Based Subtype Pharmacophore and QSAR Models	171
8.4.2	Ligand-Based Subtype Pharmacophores	179
8.4.3	Receptor-Based Subtype Pharmacophore and Ligand–Target/Antitarget Interaction-Based QSAR	181
8.5	Antitarget Modeling of Biogenic Amine-Binding GPCRs: Common Features and Subtle Differences	182
8.6	Conclusions	183
8.6.1	From Molecules to Pharmacophores to Descriptors to Models	183
8.7	Perspectives	184
8.7.1	Pharmacophore Combination Approach: From Lock and Key to Passe–Partout Model	184
	References	186

### III Antitargets: Cytochrome P450s and Transporters 195

9	<b>Cytochrome P450s: Drug–Drug Interactions</b>	197
	<i>Dan Rock, Jan Wahlstrom, Larry Wienkers</i>	
9.1	Introduction	197
9.1.1	CYP1A Subfamily	199
9.1.2	CYP2C Subfamily	200
9.1.3	CYP2D6	201
9.1.4	CYP3A Subfamily	201
9.2	Reversible Inhibition	203
9.2.1	Bioanalytical Techniques	204
9.2.2	Reagent Selection and Reaction Conditions	206
9.2.3	Experimental Design	213
9.3	Irreversible Inhibition	217
9.3.1	Identification of Mechanism-Based Inhibitor	220
9.3.2	Characterization of Mechanism-Based Inhibition	222
9.3.3	Additional Mechanistic Tools for Investigating Mechanism-Based Inhibition	225
9.4	Conclusion	230
	References	231
10	<b>Site of Metabolism Predictions: Facts and Experiences</b>	247
	<i>Ismael Zamora</i>	
10.1	Introduction	247
10.2	Factors That Influence the Site of Metabolism Prediction by Cytochrome P450s	248

10.2.1	Chemical Reactivity	249
10.2.2	Protein/Compound Interaction	249
10.3	Methods to Predict the Site of Metabolism	250
10.3.1	Knowledge-Based Methods	251
10.3.2	From Protein Structure to Chemical Reactivity	251
10.3.2.1	Docking	251
10.3.2.2	MetaSite	252
10.3.2.3	Quantum Chemistry	252
10.4	The Influence of the Protein Structure on the Site of Metabolism	253
10.4.1	Comparative Analysis Between the Different CYP Crystal Structures	253
10.4.1.1	CYP1A2	253
10.4.1.2	CYP2C5	255
10.4.1.3	CYP2B4	256
10.4.1.4	CYP2C9	256
10.4.1.5	CYP2D6	257
10.4.1.6	CYP3A4	257
10.4.2	The Effect of the Structure in the Different Methods to Predict the Site of Metabolism	259
10.5	Conclusions	260
	References	262

## 11 Irreversible Cytochrome P450 Inhibition: Common Substructures and Implications for Drug Development 267

*Sonia M. Poli*

11.1	Introduction	267
11.2	Overview	268
11.2.1	Characteristics of Irreversible CYP Inhibition	268
11.2.2	Quantitative Prediction of Drug–Drug Interaction Caused by Irreversible CYP Inhibitors	269
11.2.3	Irreversible CYP Inhibition and Autoimmune Diseases	269
11.3	Structural Features Often Responsible for Mechanism-Based CYP Inhibition	270
11.3.1	Terminal Acetylenes ( $\omega$ or $\omega-1$ )	271
11.3.2	Alkenes	271
11.3.3	Furans and Thiophenes	273
11.3.4	Secondary and Tertiary Amines	273
11.3.5	Benzodioxoles (MDP)	273
11.4	Conclusions	274
	References	274

## 12 MetaSite: Understanding CYP Antitarget Modeling for Early Toxicity Detection 277

*Yasmin Aristei, Gabriele Cruciani, Sergio Clementi, Emanuele Carosati, Riccardo Vianello, Paolo Benedetti*

12.1	Introduction	277
------	--------------	-----

12.2	The CYPs as Antitarget Enzymes	278
12.3	The UGTs as Antitarget Enzymes	279
12.4	The MetaSite Technology	282
12.4.1	Mechanism-Based Inhibitors	285
12.4.2	Phase II Metabolism by UGTs	287
12.4.3	The Flowchart of the Overall Method	287
12.5	Conclusions	289
12.6	Software Package	290
	References	290
<b>13</b>	<b>Orphan Nuclear Receptor PXR-Mediated Gene Regulation in Drug Metabolism and Endobiotic Homeostasis</b>	<b>293</b>
	<i>Jie Zhou, Yonggong Zhai, Wen Xie</i>	
13.1	Cloning and Initial Characterization of PXR	293
13.2	PXR and Its Regulation of Drug-Metabolizing Enzymes and Transporters	295
13.2.1	PXR in Phase I CYP Enzyme Regulation	295
13.2.2	PXR in Phase II Enzyme Regulation	296
13.2.2.1	PXR in UGT Regulation	296
13.2.2.2	PXR in SULT Regulation	296
13.2.2.3	PXR in GST Regulation	297
13.2.3	PXR in Drug Transporter Regulation	298
13.3	Crosstalk Between PXR and Other Nuclear Receptors	298
13.4	Implications of PXR-Mediated Gene Regulation for Drug Metabolism and Pathophysiology	299
13.4.1	PXR in Drug Metabolism and Drug–Drug Interactions	300
13.4.1.1	PXR in Drug Metabolism	300
13.4.1.2	PXR in Drug–Drug Interactions	300
13.4.1.3	Enantiospecificity of PXR-Activating Drugs and its Implication in Drug Development	301
13.4.2	Endobiotic Function of PXR	302
13.4.2.1	PXR in Bile Acid Detoxification and Cholestasis	302
13.4.2.2	PXR in Bilirubin Detoxification and Clearance	303
13.4.2.3	PXR in Adrenal Steroid Homeostasis and Drug–Hormone Interactions	303
13.4.2.4	PXR in Lipid Metabolism	304
13.5	Species Specificity of PXR and the Creation of “Humanized” Mice	304
13.5.1	Challenges of using Rodents as Drug Metabolism Models	304
13.5.2	Species Specificity of the Rodent and Human PXR	305
13.5.3	Creation and Characterization of the hPXR “Humanized” Mice	305
13.5.4	Significance of Humanized Mice in Drug Metabolism Studies and Drug Development	307
13.6	Conclusions	307
	References	310

<b>14</b>	<b>Ligand Features Essential for Cytochrome P450 Induction</b>	<b>317</b>
	<i>Daniela Schuster, Theodora M.Steindl, Thierry Langer</i>	
14.1	Introduction	317
14.2	Molecular Mechanisms Leading to P450 Induction	318
14.2.1.1	Heteroactivation	318
14.2.1.2	Activation of Nuclear Receptors	319
14.2.2	Ligands Directly Inducing P450 Activity	319
14.2.2.1	P450 2C9 Heteroactivators	319
14.2.2.2	P450 3A4 Heteroactivators	322
14.2.3	P450 Inducers Acting via Nuclear Receptors	322
14.2.3.1	Pregnane X Receptor	322
14.2.3.2	Constitutive Androstane Receptor	325
14.2.3.3	Farnesoid X Receptor	326
14.2.3.4	Liver X Receptors	328
14.2.4	P450 Inducers Acting via Transcription Factors	330
14.2.4.1	Aryl Hydrocarbon Receptor	330
14.3	General Ligand Features Leading to NR Activation	332
	References	333
<b>15</b>	<b>Transporters and Drugs – An Overview</b>	<b>341</b>
	<i>Hartmut Glaeser, Martin F. Fromm, Jörg König</i>	
15.1	Introduction	341
15.2	Organic Anion Transporting Polypeptides and Drug Transport	342
15.3	Multidrug Resistance Proteins and Drug Transport	346
15.4	Role of P-Glycoprotein for Drug Disposition	349
15.5	Vectorial Drug Transport	352
	References	355
<b>16</b>	<b>Computational Models for P-Glycoprotein Substrates and Inhibitors</b>	<b>367</b>
	<i>Patrizia Crivori</i>	
16.1	P-Glycoprotein Structure, Expression, Mechanism of Transport and Role on Drug Pharmacokinetics	367
16.2	<i>In Vitro</i> Models for Studying P-gp Interacting Compounds	369
16.3	Computational Models for Predicting P-gp Interacting Compounds	371
16.3.1	Ligand-Based Approach	372
16.3.2	Protein and Ligand–Protein Interaction-Based Approaches	387
16.4	Computational Models for Other Important Drug Transporters	389
16.5	Conclusions	390
	References	392

<b>IV</b>	<b>Case Studies of Drug Optimization Against Antitargets</b>	<b>399</b>
<b>17</b>	<b>Selective Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: The Discovery of JANUVIA<sup>®</sup> (Sitagliptin)</b>	<b>401</b>
	<i>Scott D. Edmondson, Doo-seop Kim</i>	
17.1	Introduction	401
17.2	Selectivity of DPP-4 Inhibitors	402
17.3	$\alpha$ -Amino Acid Amide Series	406
17.3.1	Cyclohexylglycines and Related Derivatives	406
17.3.2	$\beta$ -Substituted Phenylalanines as Potent and Selective DPP-4 Inhibitors	407
17.4	Early $\beta$ -Amino Acid Amide DPP-4 Inhibitors	411
17.4.1	Discovery of JANUVIA <sup>®</sup> (Sitagliptin) and Related Structure–Activity Relationships	413
17.5	Conclusions	416
	References	417
<b>18</b>	<b>Strategy and Tactics for hERG Optimizations</b>	<b>423</b>
	<i>Craig Jamieson, Elizabeth M. Moir, Zoran Rankovic, Grant Wishart</i>	
18.1	Introduction	423
18.1.1	Classification of Optimization Literature	423
18.1.1.1	Discrete Structural Modifications	424
18.1.1.2	Formation of Zwitterions	425
18.1.1.3	Control of $\log P$	425
18.1.1.4	Attenuation of $pK_a$	425
18.2	Survey of Strategies Used to Diminish hERG	426
18.2.1	Discrete Structural Modifications	426
18.2.2	Formation of Zwitterions	434
18.2.3	Control of $\log P$	440
18.2.4	Attenuation of $pK_a$	444
18.3	Summary and Analysis	448
18.3.1	Summary of Optimization Literature	448
18.3.2	Global Analysis of Reported Optimizations	448
18.3.3	Summary and Recommendations	449
18.3.4	Future Directions	450
	References	451
<b>19</b>	<b>Structure-Based <i>In Silico</i> Driven Optimization: Discovery of the Selective 5-HT<sub>1A</sub> Agonist PRX-00023</b>	<b>457</b>
	<i>Oren M. Becker</i>	
19.1	Introduction	457
19.2	Structure-Based <i>In Silico</i> Driven Multidimensional Optimization Paradigm	459
19.3	Clinical Candidate Selection Criteria	461

19.4	Lead Identification	461
19.5	Optimization Round 1: Reducing Off-Target Activities	462
19.6	Optimization Round 2: Reducing Affinity to hERG	468
19.7	Conclusion	471
	References	472

<b>Index</b>	477
--------------	-----



## List of Contributors

***Yasmin Aristei***

University of Perugia  
Chemistry Department  
Laboratory for Chemometrics  
and Cheminformatics  
Via Elce di Sotto 10  
06123 Perugia  
Italy

***Oren M. Becker***

Epix Pharmaceuticals Ltd.  
3 Hayetzira St.  
Ramat Gan 52521  
Israel

Current address:

Dynamix Pharmaceuticals  
12 Motza Ha-Qetana  
Mevasserei Zion 90805  
Israel

***Paolo Benedetti***

Molecular Discovery Ltd  
215 Marsh Road  
Pinner, Middlesex  
HA5 5NE London  
United Kingdom

***Emanuele Carosati***

University of Perugia  
Chemistry Department  
Laboratory for Chemometrics  
and Cheminformatics  
Via Elce di Sotto 10  
06123 Perugia  
Italy

***Andrea Cavalli***

Department of Pharmaceutical Sciences  
University of Bologna  
Via Belmeloro 6  
40126 Bologna  
Italy

***Sergio Clementi***

University of Perugia  
Chemistry Department  
Laboratory for Chemometrics  
and Cheminformatics  
Via Elce di Sotto 10  
06123 Perugia  
Italy

***Patrizia Crivori***

Nerviano Medical Sciences  
Accelera, Pharmacokinetic & Modeling/  
Modeling  
Viale Pasteur 10  
20014 Nerviano  
Italy

**Gabriele Cruciani**

University of Perugia  
Chemistry Department  
Laboratory for Chemometrics  
and Cheminformatics  
Via Elce di Sotto 10  
06123 Perugia  
Italy

**Sarah Dalibalta**

University of Leicester  
Department of Cell Physiology and  
Pharmacology  
Medical Sciences Building  
University Road  
Leicester LE1 9HN  
United Kingdom

**Pier G. De Benedetti**

University of Modena and Reggio Emilia  
Department of Chemistry and  
Advanced Scientific  
Computing Laboratory  
Via Campi 183  
41100 Modena  
Italy

**Fabrizio De Ponti**

University of Bologna  
Department of Pharmacology  
Via Irnerio 48  
40126 Bologna BO  
Italy

**Philippe Dupuis**

Cerep SA  
Le bois l'Eveque  
86600 Celle L'Evescault  
France

**Scott D. Edmondson**

Merck Research Laboratories  
Department of Medicinal Chemistry  
P.O. Box 2000, RY123-234  
Rahway, NJ 07065  
USA

**Andreas Evers**

Sanofi-Aventis Deutschland GmbH  
Chemical Analytical Sciences  
Drug Design  
Building G838  
65926 Frankfurt am Main  
Germany

**Francesca Fanelli**

University of Modena and Reggio Emilia  
Dulbecco Telethon Institute and  
Department of Chemistry  
Via Campi 183  
41100 Modena  
Italy

**Martin F. Fromm**

University of Erlangen-Nuremberg  
Institute of Experimental and Clinical  
Pharmacology and Toxicology  
Fahrstr. 17  
91054 Erlangen  
Germany

**Hartmut Glaeser**

University of Erlangen-Nuremberg  
Institute of Experimental and Clinical  
Pharmacology and Toxicology  
Fahrstr. 17  
91054 Erlangen  
Germany

**Craig Jamieson**

Organon Laboratories Ltd  
Medicinal Chemistry  
Newhouse  
Lanarkshire  
ML1 5SH  
United Kingdom

**Dooseop Kim**

Merck Research Laboratories  
Department of Medicinal Chemistry  
P.O. Box 2000, RY800-C206  
Rahway, NJ 07065  
USA

**Thomas Klabunde**

Sanofi-Aventis Deutschland GmbH  
 Science & Medical Affairs  
 Drug Design  
 Building G878  
 65926 Frankfurt am Main  
 Germany

**Jörg König**

University of Erlangen-Nuremberg  
 Institute of Experimental and Clinical  
 Pharmacology and Toxicology  
 Fahrstr. 17  
 91054 Erlangen  
 Germany

**Christian Laggner**

University of Innsbruck  
 Department of Pharmaceutical  
 Chemistry  
 CAMD Group  
 Innrain 52c  
 6020 Innsbruck  
 Austria

**Thierry Langer**

University of Innsbruck  
 Department of Pharmaceutical  
 Chemistry  
 CAMD Group  
 Innrain 52c  
 6020 Innsbruck  
 Austria

**Jonathan S. Mason**

Lundbeck Research  
 Ottiliavej 9  
 2500 Valby  
 Denmark

**Jacques Migeon**

Cerep SA  
 Le bois l'Eveque  
 86600 Celle L'Evescault  
 France

**John S. Mitcheson**

University of Leicester  
 Department of Cell Physiology and  
 Pharmacology  
 Medical Sciences Building  
 University Road  
 Leicester LE1 9HN  
 United Kingdom

**Elizabeth M. Moir**

Organon Laboratories Ltd  
 Medicinal Chemistry  
 Newhouse  
 Lanarkshire  
 ML1 5SH  
 United Kingdom

**Annie Otto-Bruc**

Cerep SA  
 Le bois l'Eveque  
 86600 Celle L'Evescault  
 France

**Sonia Maria Poli**

Addex Pharma  
 Non-Clinical Development  
 12, Chemin des Aulx  
 1228 Plan-Les-Ouates – GE  
 Switzerland

**Zoran Rankovic**

Organon Laboratories Ltd  
 Medicinal Chemistry  
 Newhouse  
 Lanarkshire  
 ML1 5SH  
 United Kingdom

**Maurizio Recanatini**

University of Bologna  
 Department of Pharmaceutical Sciences  
 Via Belmeloro 6  
 40126 Bologna  
 Italy

**Dan Rock**

Amgen Inc.  
1201 Amgen Court West  
Seattle, WA 98119  
USA

**Bryan L. Roth**

UNC Chapel Hill School of Medicine  
Medicinal Chemistry  
Burnett Womack Building; Room 8032  
UNC Chapel Hill  
Chapel Hill, NC  
USA

**Daniela Schuster**

University of Innsbruck  
Department of Pharmaceutical  
Chemistry  
CAMD Group  
Innrain 52c  
6020 Innsbruck  
Austria

**Vincent Setola**

INSERM  
U616 Hôpital Pitié-Salpêtrière  
Paris  
France

**Theodora M. Steindl**

Inte:Ligand Softwareentwicklungs- und  
Consulting GmbH  
Clemens-Maria-Hofbauer-G. 6  
2344 Maria Enzersdorf  
Austria

**Riccardo Vianello**

Molecular Discovery Ltd  
215 Marsh Road, Pinner  
Middlesex  
HA5 5NE London  
United Kingdom

**Jan Wahlstrom**

Amgen Inc.  
1201 Amgen Court West  
Seattle, WA 98119  
USA

**Larry Wienkers**

Amgen Inc.  
1201 Amgen Court West  
Seattle, WA 98119  
USA

**Grant Wishart**

Organon Laboratories Ltd  
Medicinal Chemistry  
Newhouse  
Lanarkshire  
ML1 5SH  
United Kingdom

**Wen Xie**

University of Pittsburgh  
Center for Pharmacogenetics  
633 Salk Hall  
Pittsburgh, PA 15216  
USA

**Ismael Zamora**

Pompeu Fabra University  
GRIB-IMIM  
Dr Aiguader 80  
E080003 Barcelona  
Spain

**Yonggong Zhai**

Beijing Normal University  
Biomedicine Research Institute and  
College of Life Science  
Beijing 100875  
China

**Jie Zhou**

University of Pittsburgh  
Center for Pharmacogenetics  
633 Salk Hall  
Pittsburgh, PA 15216  
USA

## Preface

When the hammer hits your thumb in addition to, or instead of the nail - this clearly is an antitarget problem. In drug action and especially in drug-drug interactions, the situation is much more serious. There are numerous targets which should not be activated, induced, or inhibited by a drug. Adverse drug reactions (ADRs) are estimated to be one of the leading causes of morbidity and mortality in healthcare. Especially older patients receive up to 15 different medications, and even more, at the same time – no wonder that unfavorable drug-drug interactions happen, considering also the poor physical condition of such patients. In January 2000, the Institute of Medicine reported that in the US about 7000 deaths per year occur due to ADRs; the number may be even much larger, not to count the manyfold non-fatal side effects.

In defining the term “antitarget” one runs into some problems. Let us start with terfenadine, a non-sedating H1-antihistaminic. In its clinical studies it was obviously safe, with only minor side effects. However, after its broad therapeutic use it turned out to produce fatal arrhythmias. In addition to being an H1 antagonist, terfenadine is a potent hERG channel inhibitor. Under normal conditions, terfenadine is already metabolized in the intestinal wall; no measurable plasma levels and no cardiac side effects are observed. If CYP inhibitors prevent terfenadine metabolism, cardiac toxicity results. Thus, in addition to its H1 receptor antagonism, the compound inhibits the hERG channel, a most prominent antitarget. The terfenadine problem could be circumvented by replacing the compound by its active metabolite fexofenadine, which is not any longer a hERG channel inhibitor.

Already around 1990, David Bailey discovered that grapefruit (but not orange) juice significantly increases the bioavailability of some drugs, for example the calcium channel blockers felodipine and nifedipine. After some problems to publish this highly surprising observation, his manuscript was accepted by *Lancet* and many reports followed for other drugs. The whole story shall not be elaborated here in detail but it remains the question: is CYP3A4, which is inhibited by some flavonoid and furocoumarin constituents of grapefruit juice, an antitarget? It is: despite the fact that increase in bioavailability is a desirable effect, individual variation is too large to be of therapeutic value. Only in the case of clinically monitored drugs, for example cyclosporin, the co-medication of a CYP3A4 inhibitor, for example ketoconazole, is used to reduce the dose of this expensive drug.

Recently it was discovered that grapefruit juice also induces the expression of intestinal drug transporters. With fexofenadine, the safe replacement of terfenadine, the paradox situation results that bioavailability of this drug decreases (!) after intake of grapefruit juice, due to induction of an efflux pump, the organic anion-transporting polypeptide 1A2 (OATP1A2). Kirby and Unadkat commented this paradox by asking the question "Grapefruit juice, a glass full of drug interactions?"

Not only food constituents but also OTC drugs may cause significant drug-drug interactions. One of the well-known examples is St. John's Wort (*Hypericum perforatum* L.) extract, supposed to be beneficial against mild depression. However, in addition to the phototoxic agent hypericin, the plant contains hyperforin, the strongest inducer of CYPs (especially CYP3A4) and drug transporters. In this manner, self-medication with St. John's Wort reduces the bioavailability and thus the activity of several drugs, whereas doses of some drugs have to be reduced after discontinuation of this extract because CYP and transporter levels return to normal.

There are many more antitargets, prominent ones being several G protein-coupled receptors. Thus, it is high time that a book on antitargets becomes available and we, as Editors of the series *Methods and Principles in Medicinal Chemistry*, are very much indebted to Roy Vaz and Thomas Klabunde, leading scientists in antitarget research, for editing such a monograph. The book starts with an introduction on the reasons why drugs fail in the clinics or after market introduction and a chapter on ADME and side effects prediction. The main two sections contain several chapters on antitargets and side effects (hERG channel and GPCR antitargets) and on antitargets in ADME (CYPs and drug transporters). The book concludes with some case studies of drug optimization against antitargets.

We are very grateful to all chapter authors and we thank the publisher Wiley-VCH, especially Dr. Frank Weinreich, for the ongoing support of our series, and Dr. Nicola Oberbeckmann-Winter for her contributions in the preparation of this volume.

October 2007

Raimund Mannhold, Düsseldorf  
Hugo Kubinyi, Weisenheim am Sand  
Gerd Folkers, Zürich

## A Personal Foreword

A single report of a drug reaction in a 39-year-old woman ultimately contributed to the removal of the allergy drug Seldane (terfenadine) from the market in 1998 [1]. Doctors at the National Naval Medical Center in Bethesda, Md., admitted the woman to the hospital because of fainting episodes. She had been prescribed Seldane (terfenadine) 10 days before. She also started using the prescription drug Nizoral (ketoconazole) for a vaginal yeast infection. That combination caused potentially fatal changes in her heart rhythm. The Food and Drug Administration (FDA) issued warnings indicating that ketoconazole interfered with terfenadine's metabolism, which resulted in increased levels of terfenadine in the blood and slowed its elimination from the body. The FDA also warned that a similar effect could occur if Seldane was taken with the antibiotic erythromycin.

Thus the first awareness of antitargets was brought to the forefront with the withdrawal of terfenadine. Ketoconazole is a strong inhibitor of CYP3A4, which is also the primary enzyme responsible for the clearance of terfenadine. The inhibition of CYP3A4 leads to the increase in concentration of terfenadine in the blood. Terfenadine itself is a blocker of the ion channel hERG (human ether-a-go-go related gene) and caused a prolonged QT, leading to Torsades de Pointes and possibly death. Also ketoconazole inhibits the efflux transporter P-glycoprotein (P-gp) or MDR1 (multidrug resistance protein), for which terfenadine is a substrate. Hence when co-administered with ketoconazole, the concentration of terfenadine in blood would be much higher than if taken without other drugs such as ketoconazole. Therefore inhibition of both P-gp and CYP3A4 could lead to drug-drug interactions and inhibition of hERG either by the compound itself or its metabolite.

The example of terfenadine shows that toxic effects can be either induced directly by the action of a drug or a drug metabolite on an antitarget like the hERG channel. In addition, certain transporters and metabolizing enzymes, like P-gp and CYP3A4, need also be considered as antitargets as blocking their activity can change the concentration of a co-administered drug or its metabolite in blood, thus causing drug-drug interactions and potential toxicity.

Adverse drug reactions (ADRs) cost approximately one hundred and thirty nine billion dollars annually [2–4] in the United States. This number is larger than the

cost of cardiovascular or diabetic care. ADRs cause 1 out of 5 injuries or deaths per year to hospitalized patients and the mean length of stay, the cost and the mortality for patients admitted due to an ADR are double that for control patients. Many ADRs are due to off-target and antitarget interactions. Some of these have led to withdrawal of the drug(s) from the marketplace.

Since terfenadine, there have been other market withdrawals of drugs. As shown in the first chapter of the book the main cause for the 16 drug withdrawals from 1992 to 2002 was toxicity, mainly cardiovascular toxicity or hepatotoxicity. Only recently Vioxx (rofecoxib) had to be withdrawn from the market. In contrast to terfenadine, where the molecular mechanism of its side effects has been fully understood, the underlying mechanism by which rofecoxib, a selective cyclooxygenase 2 inhibitor that exhibits cardiovascular effects is still unclear [5]. Pondimin (fenfluramine), a serotonergic anorectic, was withdrawn in 1997 due to the risk of development of primary pulmonary hypertension or valvular heart disease. The first case of fenfluramine associated valvular heart disease discovered 7 years after discontinuation of treatment and requiring double valve replacement 2 years later has just been reported [6]. For fenfluramine the mechanism by which it causes valvular heart disease has recently been uncovered showing a causal association between agonism on the G-protein coupled receptor (GPCR) 5-HT<sub>2B</sub> and valvular heart disease (Chapter 7 in the book).

According to FDA experts, discovering terfenadine's interactions with other drugs marked a significant advance. These and other discoveries improved the ability of the FDA and drug manufacturers to test for drug interactions and to investigate risks of heart rhythm abnormalities and other toxicities before drugs could be marketed. In addition, unraveling the mechanism of drug toxicities and identifying specific channels, receptors including nuclear receptors, transporters or enzymes as antitargets enabled establishment of *in vitro* test systems to monitor potential antitarget mediated side effects and toxicity in the drug discovery phase. The list of antitargets is still being compiled but the events that have led to the discovery of the known antitargets has impacted the way research is conducted during drug discovery today.

In every family of biological targets there are antitargets. In this book, we have avoided discussion of kinases, which are still controversial as non-oncology targets and could probably command several chapters or volumes. Transporters and metabolizing enzymes like CYP450s that can mediate undesired drug-drug interactions have been mentioned before. In the area of potassium voltage-gated ion channels, there are therapeutic targets such as Kv1.3 and Kv1.5 but at the same time there are antitargets such as hERG. GPCRs form a large protein family that plays an important role in many physiological and patho-physiological processes. Especially the sub-family of biogenic amine binding GPCRs has provided excellent drug targets for the treatment of numerous diseases [7]. Although representing excellent therapeutic targets, the central role that many of the biogenic amine binding GPCRs play in cell signaling also poses a risk on new drug candidates which reveal side-affinities towards these receptor sites: These candidates bear the risk to interfere with the physiological signaling process and to cause undesired effects in preclinical or



clinical studies. Besides the 5-HT<sub>2B</sub> receptor mentioned before, the  $\alpha_{1A}$  adrenergic receptor, being a drug target for the treatment of benign prostatic hypertrophy (BPH), has been suggested as an antitarget at the same time that mediates cardiovascular side-effects of many drug candidates causing orthostatic hypotension, dizziness and fainting spells [8]. Other examples of GPCR antitargets are the muscarinic M1 receptor correlated with attention and memory deficits or the serotonin 5-HT<sub>2C</sub> receptor associated with weight gain. As shown in one of the introductory chapters of this book, correlation between *in vitro* affinity and *in vivo* adverse effects can currently be recognized by profiling, hundreds of drugs with known ADRs using large panels of pharmacological *in vitro* assays.

There are several references made to both off-targets as well as antitargets in the literature. In this book we will primarily be attempting to cover the topic of antitargets. Off-target activity the way we interpret it, is activity for a particular compound towards a target that was not anticipated, when it was synthesized or isolated. For example, compounds that are designed or synthesized for activity towards serine proteases (not for thrombosis) are not expected to have any activity towards serine protease targets such as thrombin or others in the coagulation pathway, which could be anti-thrombotic targets themselves. The term off-targets includes antitargets and the off-target activities could be beneficial or detrimental. Antitargets on the other hand are targets that are detrimental towards progression of the compound towards becoming a drug.

Within recent years the understanding of the molecular interactions between antitargets and drugs or drug candidates has tremendously increased allowing *in silico* antitarget models to be established. 3-dimensional structures of several antitargets (often in complex with inhibitors) are now available either derived by homology modeling (e.g. the hERG channel or GPCRs) or by protein crystallography (e.g. cytochrome P450s). Structural chemical motifs often associated with antitarget interactions (e.g. for cytochrome P450 binding or inhibition) have been captured in knowledge databases. Computational models like 3D-pharmacophore or 3D-QSAR models (e.g. for GPCRs, hERG, CYPs, P-gp) have been established to not only recognize antitarget affinities in chemical lead series but also to guide the chemical optimization of these leads towards development candidates lacking undesired antitarget side affinities and thus potential side effects or toxicities. These models are captured – together with introductory chapters on the biological aspects – in the second (focusing on ion channels and GPCRs) and the third section of this book (describing antitargets mediating drug-drug interactions).

Examples of optimization of selectivity towards the antitargets have been well described in the recent literature such as illustrated in Gao *et al.* [9] and Kuduk *et al.* [10]. In the last section we have tried to include very specific case studies of successful drugs for which optimization of selectivity towards specific or general antitargets were successfully negotiated, e.g. for Januvia (chapter 17), a recently released DPP4 inhibitor or for PRX-00023, a selective 5-HT<sub>1A</sub> agonist currently in phase IIb clinical trials (chapter 19).

We would first thank the editors of the series for enabling this volume in the Methods and Principles in Medicinal Chemistry series. We would like to sincerely

thank all chapter authors for making this book a reality. We would like to acknowledge their great enthusiasm in preparing their manuscripts and the high quality of their contributions. It has been a pleasure working with each and every one of them. The editors are also grateful to Frank Weinreich, Nicola Oberbeckmann-Winter and the staff of Wiley-VCH for their excellent support in the production of this book. We also thank the Sanofi-Aventis Discovery Management for enabling this book. We thank our families for putting up with us during the last few months.

October 2007

Roy Vaz, Bridgewater  
Thomas Klabundl, Frankfurt

## References

- 1 Monahan, B.P., Ferguson, C.L., Kileavy, E.S., Lloyd, B. K., Troy, J., Cantilena, L.R. (1990) Torsades de Pointes occurring in association with Terfenadine use. *The Journal of the American Medical Association*, **264**, 2788–2790.
- 2 Johnson J.A., Bootman, J.L. (1995) Drug-related morbidity and mortality. A cost-of-illness model. *Archives of Internal Medicine*, **155** (18), 1949–1956.
- 3 Leape, L.L., Brennan, T.A., Laird, N., Lawthers, A.G., Localio, A.R., Barnes, B.A., Hebert, L., Newhouse, J.P., Weiler, P.C., Hiatt, H.H. (1991) The nature of Adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. *The New Journal of Medicine*, **324** (6), 377–394.
- 4 Classen D.C., Pestotnik, S.L., Evans, R.S., Lloyd, J.F., Burke, J.P. (1997) Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. *The Journal of the American Medical Association*, **277** (4), 301–306.
- 5 Zarraga, I.G.E., Schwarz, E.R. (2007) Coxibs and Heart Disease. *Journal of the American College of Cardiology*, **49** (1), 1–149.
- 6 Greffe, G., Chalabreysse, L., Mouly-Bertin, C., Lantelme, P., Thivolet, F., Aulagner, G., Obadia, J-F. (2007) Valvular Heart Disease associated with Fenfluramin Detected 7 Years after Discontinuation of Treatment. *The Annals of Thoracic Surgery*, **83**, 1541–1543.
- 7 Klabunde, T., Hessler, G. (2002) Drug design strategies for targeting G-protein-coupled receptors. *A European Journal of Chemical Biology*, **3**, 928–944.
- 8 Kehne, J.H., Baron, B.M., Carr, A. A., Chaney, S. F., Elands, J., Feldman, D. J., Frank, R. A., van Giersbergen, P. L., McCloskey, T. C., Johnson, M.P., McCarty, D. R., Poirot, M., Senyah, Y., Siegel, B. W., Widmaier, C. (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT<sub>2A</sub> antagonist with a favorable CNS safety profile. *The Journal of Pharmacology and Experimental Therapeutics*, **277**, 968–981.
- 9 Gao, Y.D., Olson, S.H., Balkovec, J.M., Zhu, Y., Royo, I., Yabut, J., Evers, R., Tan, E.Y., *et al.* (2007) Attenuating pregnane X receptor (PXR) activation: A molecular modeling approach. *Xenobiotica*, **37** (2), 124–138.
- 10 Kuduk, S.D., DiMarco, C.N., Chang, R.K., Wood, M.R., Schirripa, K.M., Kim, J.J., Wai, J.M.C., DiPardo, R.M. *et al.* (2007) Development of Orally Bio-available and CNS Penetrant Biphenyla-minocyclopropane Carboxamide Bradykinin B1 Receptor Antagonists. *Journal of Medicinal Chemistry*, **50**, 272–282.

## I

**General Aspects**



# 1

## Why Drugs Fail – A Study on Side Effects in New Chemical Entities

Daniela Schuster, Christian Laggner, Thierry Langer

### 1.1

#### Introduction


Drug development is a long and cost-intensive business. Only after years of lead identification, chemical optimization, *in vitro* and animal testing can the first clinical trials be conducted. Unfortunately, many projects still fail in this late stage of development after a considerable amount of money has been spent. According to estimates, preapproval costs for a new drug exceed US\$ 800 million [1].

Approximately 10% of new chemical entities (NCEs) show serious adverse drug reactions (ADRs) after market launch. Such events usually result in ‘new black box warnings’ by the US Food and Drug Administration (FDA), label change or market withdrawal. The most common causes for these actions are hepatic toxicity, hematologic toxicity and cardiovascular toxicity [2]. Reasons for such ADRs, which are identified only after NCEs are launched on the market, include the narrow spectrum of clinical disorders and participating patient profiles in clinical studies as well as the fact that serious ADRs are often rare and that the number of patient exposures required to identify such occurrences sometimes may range over a few millions [3].


To avoid the occurrence of ADRs in the future, specific trials to detect them should therefore be conducted before an NCE is launched on the market. Before this can be done, however, the major reasons leading to the withdrawal of drugs and termination of NCE-to-drug development should be identified and analyzed.

In this chapter, reasons why 17 drugs were withdrawn from the Western market between 1992 and 2006 are discussed and facts on 63 terminated clinical development projects presented, so as to identify the most common reasons for the failure of drugs in this late stage of drug development. This analysis is then compared with two previous related studies published more than 18 years ago by Prentis *et al.* [4] and Kennedy [5].

The study by Prentis *et al.* [4] included an analysis of 198 NCEs, developed between 1964 and 1985 by British pharmaceutical companies but had not been marketed for reasons presented in Figure 1.1. Kennedy [5] further analyzed these data and noticed that a high number of anti-infective drug development projects were all terminated



**Figure 1.1** Reasons for drug development termination from 1964 to 1985 ( $n = 198$ ).



**Figure 1.2** Reasons for drug development termination, excluding anti-infectives ( $n = 121$ ).

because of pharmacokinetic difficulties. He therefore excluded the anti-infective NCEs from the statistics and presented the facts as illustrated in Figure 1.2.

## 1.2

### Drugs Withdrawn from the Market between 1992 and 2006 Listed Alphabetically

#### 1.2.1

##### Amineptine

The atypical tricyclic antidepressant amineptine (Survector) is an indirect dopamine agonist, which selectively inhibits dopamine uptake and induces its release, with additional stimulation of the adrenergic system. Its antidepressant effects are similar to those of other tricyclic antidepressant drugs. However, it acts more rapidly, is better